Biocartis Group Nv Stock Price To Earnings To Growth
BCART Stock | EUR 0.29 0.00 0.00% |
Biocartis Group NV fundamentals help investors to digest information that contributes to Biocartis Group's financial success or failures. It also enables traders to predict the movement of Biocartis Stock. The fundamental analysis module provides a way to measure Biocartis Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biocartis Group stock.
Biocartis |
Biocartis Group NV Company Price To Earnings To Growth Analysis
Biocartis Group's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Based on the latest financial disclosure, Biocartis Group NV has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all Belgium stocks is 100.0% higher than that of the company.
Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
All Next | Launch Module |
Biocartis Fundamentals
Return On Equity | -48.84 | |||
Return On Asset | -0.22 | |||
Profit Margin | (1.07) % | |||
Operating Margin | (0.85) % | |||
Current Valuation | 182.31 M | |||
Shares Outstanding | 93.1 M | |||
Shares Owned By Insiders | 6.66 % | |||
Shares Owned By Institutions | 27.71 % | |||
Price To Earning | (9.91) X | |||
Price To Book | 6.47 X | |||
Price To Sales | 0.89 X | |||
Revenue | 48.27 M | |||
Gross Profit | (25.72 M) | |||
EBITDA | (52.55 M) | |||
Net Income | (71.47 M) | |||
Cash And Equivalents | 53.52 M | |||
Cash Per Share | 0.93 X | |||
Total Debt | 128.15 M | |||
Debt To Equity | 40.40 % | |||
Current Ratio | 2.82 X | |||
Book Value Per Share | (1.07) X | |||
Cash Flow From Operations | (65.72 M) | |||
Earnings Per Share | (1.24) X | |||
Target Price | 1.8 | |||
Number Of Employees | 619 | |||
Beta | 1.51 | |||
Market Capitalization | 60.8 M | |||
Total Asset | 142.48 M | |||
Retained Earnings | (188 M) | |||
Working Capital | 90 M | |||
Current Asset | 118 M | |||
Current Liabilities | 28 M | |||
Z Score | -1.4 | |||
Net Asset | 142.48 M |
About Biocartis Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biocartis Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biocartis Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biocartis Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in Biocartis Stock
Biocartis Group financial ratios help investors to determine whether Biocartis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biocartis with respect to the benefits of owning Biocartis Group security.